These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35917650)

  • 41. Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia. The Risperidone Study Group.
    Nair NP
    J Clin Psychopharmacol; 1998 Apr; 18(2):103-10. PubMed ID: 9555595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM; D'Souza DC; Patkar AA; Youakim JM; Tiller JM; Yang R; Keefe RS
    J Clin Psychiatry; 2010 Nov; 71(11):1475-81. PubMed ID: 20816042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lovastatin for the adjunctive treatment of schizophrenia: a preliminary randomized double-blind placebo-controlled trial.
    Ghanizadeh A; Rezaee Z; Dehbozorgi S; Berk M; Akhondzadeh S
    Psychiatry Res; 2014 Nov; 219(3):431-5. PubMed ID: 25017614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.
    Kianimehr G; Fatehi F; Hashempoor S; Khodaei-Ardakani MR; Rezaei F; Nazari A; Kashani L; Akhondzadeh S
    Daru; 2014 Jul; 22(1):55. PubMed ID: 25012765
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
    Nikbakhat MR; Arabzadeh S; Zeinoddini A; Khalili Z; Rezaei F; Mohammadinejad P; Ghaleiha A; Akhondzadeh S
    Pharmacopsychiatry; 2016 Jul; 49(4):162-9. PubMed ID: 26902281
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.
    Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F
    J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
    Casey DE; Sands EE; Heisterberg J; Yang HM
    Psychopharmacology (Berl); 2008 Oct; 200(3):317-31. PubMed ID: 18597078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A double-blind, placebo-controlled study of traditional Chinese medicine sarsasapogenin added to risperidone in patients with negative symptoms dominated schizophrenia.
    Xiao SF; Xue HB; Li X; Chen C; Li GJ; Yuan CM; Zhang MY
    Neurosci Bull; 2011 Aug; 27(4):258-68. PubMed ID: 21788997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.
    Hirschfeld RM; Keck PE; Kramer M; Karcher K; Canuso C; Eerdekens M; Grossman F
    Am J Psychiatry; 2004 Jun; 161(6):1057-65. PubMed ID: 15169694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Akhondzadeh S; Malek-Hosseini M; Ghoreishi A; Raznahan M; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1879-83. PubMed ID: 18801405
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
    Heck AH; Haffmans PM; de Groot IW; Hoencamp E
    Schizophr Res; 2000 Dec; 46(2-3):97-105. PubMed ID: 11120421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.
    Xiao S; Xue H; Li G; Yuan C; Li X; Chen C; Wu HZ; Mitchell P; Zhang M
    Aust N Z J Psychiatry; 2012 Feb; 46(2):153-60. PubMed ID: 22311531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.
    Buitelaar JK; van der Gaag RJ; Cohen-Kettenis P; Melman CT
    J Clin Psychiatry; 2001 Apr; 62(4):239-48. PubMed ID: 11379837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Palmitoylethanolamide as adjunctive therapy for autism: Efficacy and safety results from a randomized controlled trial.
    Khalaj M; Saghazadeh A; Shirazi E; Shalbafan MR; Alavi K; Shooshtari MH; Laksari FY; Hosseini M; Mohammadi MR; Akhondzadeh S
    J Psychiatr Res; 2018 Aug; 103():104-111. PubMed ID: 29807317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
    Akhondzadeh S; Gerami M; Noroozian M; Karamghadiri N; Ghoreishi A; Abbasi SH; Rezazadeh SA
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1810-5. PubMed ID: 18727948
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
    Barnes TR; Leeson VC; Paton C; Costelloe C; Simon J; Kiss N; Osborn D; Killaspy H; Craig TK; Lewis S; Keown P; Ismail S; Crawford M; Baldwin D; Lewis G; Geddes J; Kumar M; Pathak R; Taylor S
    Health Technol Assess; 2016 Apr; 20(29):1-46. PubMed ID: 27094189
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
    Casey DE; Daniel DG; Tamminga C; Kane JM; Tran-Johnson T; Wozniak P; Abi-Saab W; Baker J; Redden L; Greco N; Saltarelli M
    Neuropsychopharmacology; 2009 Apr; 34(5):1330-8. PubMed ID: 19052541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.